Brazil Anxiety Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Disorder, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Brazil · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$298.4 MnPlaceholder estimate
Estimate 2025$310.6 Mn2.7% of the global market
Projected 2034$445.9 Mn 43.6%Adds $135.3 Mn over 9 forecast years
CAGR 2025–20344.1%Faster than 2% of 186 Pharmaceuticals markets here
Key players5
Brazil is 2.66% of the global market.
In Latin America, the largest is Brazil (this report) at $310.6 Mn.
Fastest growing: Brazil (this report) at 4.1% a year.
Brazil ranks 1st of 3 by size in Latin America.
Market size projection
Brazil
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$135.3 Mn total, 2026–2034
Year-by-year market size, 2024–2034
Anxiety Disorder Drugs Market market size by year, Brazil
Year
Market size
Change that year
Since 2025
2024 (estimate)
$298.4 Mn
—
—
2025 (base)
$310.6 Mn
+$12.2 Mn
—
2026 (forecast)
$323.3 Mn
+$12.7 Mn
+4.1%
2027 (forecast)
$336.6 Mn
+$13.3 Mn
+8.4%
2028 (forecast)
$350.4 Mn
+$13.8 Mn
+12.8%
2029 (forecast)
$364.7 Mn
+$14.4 Mn
+17.4%
2030 (forecast)
$379.7 Mn
+$15.0 Mn
+22.3%
2031 (forecast)
$395.3 Mn
+$15.6 Mn
+27.3%
2032 (forecast)
$411.5 Mn
+$16.2 Mn
+32.5%
2033 (forecast)
$428.3 Mn
+$16.9 Mn
+37.9%
2034 (forecast)
$445.9 Mn
+$17.6 Mn
+43.6%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
16 in BrazilSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Brazil Anxiety Disorder Drugs Market Analysis Executive Summary
Anxiety disorder drugs treat generalised anxiety, panic and social anxiety with antidepressants, buspirone and other medicines.
Key segments of the anxiety Disorder Drugs market include drug class (SSRIs, SNRIs and Benzodiazepines) and disorder (Generalized Anxiety, Panic Disorder and Social Anxiety).
Brazil Anxiety Disorder Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Brazil Anxiety Disorder Drugs Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the anxiety Disorder Drugs market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the anxiety Disorder Drugs market.
Competitive Landscape for Anxiety Disorder Drugs Market in Brazil
The anxiety Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Anxiety Disorder Drugs Market in Brazil
Anxiety Disorder Drugs in Brazil: rules, payment and research
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.[2] ClinicalTrials.gov lists 16 studies on Anxiety Disorder Drugs that are recruiting, active or about to start in Brazil.[3] Suicide rate: 8.8 per 100,000 people in 2023, the latest WHO figure for Brazil.[4]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anxiety Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Disorder
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Pfizer
7.2 Eli Lilly and Company
7.3 Viatris
7.4 Lundbeck
7.5 MindMed
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The anxiety Disorder Drugs market can be segmented based on various criteria, including drug class, disorder and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Anxiety Disorder Drugs right now, from free public sources.
Suicide rate: 8.8 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 3rd highest of the 7 countries we cover in Latin America.[1]
Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 7 countries we cover in Latin America.[2]
Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 7 countries we cover in Latin America.[3]
How big is the Anxiety Disorder Drugs market in Brazil?
Placeholder estimate: about $310.6 Mn in 2025, rising to about $445.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anxiety Disorder Drugs market in Brazil growing?
Placeholder estimate: about 4.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anxiety Disorder Drugs market report cover?
The report splits the market by drug class (SSRIs, SNRIs, Benzodiazepines, Buspirone and more), disorder (Generalized Anxiety, Panic Disorder, Social Anxiety) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anxiety Disorder Drugs market?
Key players include Pfizer Inc., Eli Lilly and Company, Viatris, Lundbeck and MindMed.
What is driving the Anxiety Disorder Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.
Who regulates Anxiety Disorder Drugs in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How many clinical trials on Anxiety Disorder Drugs are running in Brazil?
16 studies are recruiting, active or about to start in Brazil, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
What does WHO report for Brazil?
Suicide rate: 8.8 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 22 Nov 2026.
How many people in Brazil are 65 or older?
11.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 22 Nov 2026.